Nextech, Syncona in $80m Autolus series-C

Nextech was joined by another new investor, Cormorant Asset Management, as well as existing backers Syncona Partners, Woodford Investment Management and Arix Bioscience.

The capital will be used to establish clinical proof of concept for three programmes, as well as advancing some of its projects that are in the pre-clinical stage.

Previous funding
In January 2015, Syncona committed £30m of funding, investing alongside UCL Business, after helping to found the company in 2014.

In March 2016, the firm raised a further £40m in a series-B financing involving Woodford and Perceptive Bioscience Investments.

Company
Autolus was founded in 2014 based on the work of Dr Martin Pule, an academic clinical haematologist at the UCL Cancer Institute and NIHR University College London Hospital's Biomedical Research Centre. It is a clinical-stage biopharmaceutical company focused on the development and commercialisation of engineered T-cell therapies to combat cancer. All of its products are currently in the development stages. It currently has 100 staff.

People
Autolus – Christioan Itin (chair & CEO).
Syncona Partners – Martin Murphy (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• United Kingdom